Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...1213141516171819202122...123124»
  • ||||||||||  ETN101 / Etnova Therap
    Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5306;    
    We developed ETN101, a monotherapy that targets VEGFR2 and modulates the TME with the same mechanism as the combination therapy. ETN101 also showed excellent efficacy in preclinical study and secured a broad safety margin relative to the effective dose.
  • ||||||||||  Comparison of checkpoint inhibitor () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5277;    
    Among ICI combinations, better survival and response rates were reported with sintilimab + bevacizumab, atezolizumab + bevacizumab, and camrelizumab + rivoceranib. Therefore, these regimens should be preferred for treatment of advanced HCC as first line therapy in patients who can tolerate these regimens.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5226;    
    P=N/A
    Our retrospective study of high-risk FLC, most multiply relapsed, pretreated, stage 4 and unresectable, showed that a prolonged and meaningful clinical response and acceptable quality of life with a chance for curative surgery is possible for many young patients thought to be incurable. Prospective trials are needed to confirm these results.
  • ||||||||||  GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers. (Hall A; Poster Bd #: 163b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3916;    
    P2
    Early-phase studies have demonstrated the efficacy of volrustomig (volru; anti-PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody [mAb]) in patients (pts) with non-small-cell lung cancer (NSCLC) and renal cell carcinoma, and of rilvegostomig (rilve; anti-PD-1/TIGIT bispecific humanized IgG1 mAb) in pts with NSCLC, along with manageable safety profiles...Pts will be treated with volru as monotherapy or in combination with bevacizumab or lenvatinib...Pts will be treated with gemcitabine + cisplatin with either rilve or volru...The study is currently recruiting at sites in the US, Asia, and Europe. GEMINI-Hepatobiliary master protocol design.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma. (Hall A; Poster Bd #: 6) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3761;    
    HS-H tumors has worse OS that may be improved with Atezo, whereas HS-L tumors may respond better to Soraf. HS is a potential prognostic and predictive biomarker in HCC that deserves validation in orthogonal data sets and prospective studies.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2129;    
    P2
    Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
  • ||||||||||  AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC). (Hall A; Poster Bd #: 502b) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1954;    
    P1/2
    The Atezo+bevacizumab (biomarker unmatched) and Atezo+ipatasertib (PIK3CA/PTEN/AKT1-altered tumors) cohorts have completed accrual...AFT-50B pts will be eligible for inavolisib (PIK3CAm/PTEN and AKT1wt-altered tumors) + letrozole or giredestrant + abemaciclib (RB1wt, estrogen receptor positive tumors)...As a platform study, additional arms may be added, as supported by evolving understanding of EC and molecular targets. EndoMAP is actively enrolling at 20 sites in the US with a target of 25 sites nationwide.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer. (Hall A; Poster Bd #: 483) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1924;    
    Among TP53-mt patients, ARID1A-mt is associated with improved pembro-lenv survival but not in pembro alone. Our findings suggest a need to readdress when to use lenvatinib in TP53-mt patients and further explore genomic alterations that may promote treatment response to optimize use of this agent in endometrial cancer.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer. (Hall A; Poster Bd #: 459) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1901;    
    In addition, those who received a lower starting dose experienced fewer dose reductions but no difference in dose discontinuation due to AE. Prospective studies of dose and schedule are needed to confirm these findings and define an optimal dosing strategy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. (Hall B1) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1800;    
    P3
    Further research is essential to pinpoint the patient subset that can benefit the most from this combination. Background: In the primary analysis of CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy vs sunitinib (S) in treatment-na